<DOC>
	<DOCNO>NCT00166712</DOCNO>
	<brief_summary>This open label , single-center , randomized phase IV pilot study steroid calcineurin inhibitor avoidance renal transplant recipient . All patient receive two dos alemtuzumab achieve peripheral T-cell depletion . Intravenous glucocorticoid administer prior alemtuzumab administration limit cytokine release syndrome association monoclonal antibody , continue first two day post-transplant . Thereafter , steroid use immunosuppression . All transplant recipient start oral immunosuppressive therapy mycophenolate mofetil ( MMF ) prior transplant . Pretransplant , patient randomize receive , addition , either tacrolimus ( Tac ) sirolimus . After six month , patient tacrolimus arm experience rejection randomize continue tacrolimus convert combination sirolimus MMF . Individuals arm study experience acute rejection , demonstrate evidence donor specific hyporesponsiveness 9 month post-transplant ( stay Tac + MMF ) 3 month post-conversion ( convert Tac + MMF sirolimus + MMF ) wean MMF monotherapy . Individuals sirolimus + MMF arm experience acute rejection demonstrate evidence donor specific hyporesponsiveness 6 month post-transplant wean MMF monotherapy .</brief_summary>
	<brief_title>A Trial Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>1 . Patients male female age 1865 year 2 . Donor age 1865 year 3 . Patients singleorgan recipient ( kidney ) 4 . Women childbearing potential must negative serum pregnancy test transplantation agree use medically acceptable method contraception throughout treatment period . 5 . Subject ( recipient ) able understand consent form give write informed consent 1 . Known sensitivity contraindication sirolimus , tacrolimus MMF 2 . Patient significant active infection 3 . Patients positive lymphocytotoxic crossmatch use donor lymphocyte recipient serum 4 . Patients PRA &gt; 20 % 5 . Patients pregnant nursing mother 6 . Patients whose life expectancy severely limited disease renal disease 7 . Ongoing active substance abuse , drug alcohol 8 . Major ongoing psychiatric illness recent history noncompliance 9 . Significant cardiovascular disease ( e.g . ) : Significant noncorrectable coronary artery disease Ejection fraction 30 % History recent myocardial infarction 10 . Malignancy within 3 year , exclude nonmelanoma skin cancer 11 . Serologic evidence infection HIV HBVsAg positive 12 . Patients screening/baseline total white blood cell count &lt; 4,000/mm3 ; platelet count &lt; 100,000/mm3 ; triglyceride &gt; 400 mg/dl ; total cholesterol &gt; 300 mg/dl 13 . Investigational drug within 30 day prior transplant surgery 14 . AntiT cell therapy within 30 day prior transplant surgery 15 . Patients use Prednisone 16 . Patients ABO incompatible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Kidney Transplant</keyword>
	<keyword>Living Donor Kidney Transplant Recipients</keyword>
</DOC>